证券代码：688739 证券简称：成大生物 公告编号：2025-052 辽宁成大生物股份有限公司 关于自愿披露签订战略合作协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 合同类型：辽宁成大生物股份有限公司（简称"公司"或"成大生物"） 与中国科学院微生物研究所（简称"微生物所"）于近日签署《战略合作协议》 （简称"本协议"），双方聚焦新发突发传染病领域，重点围绕虫媒传染病预防， 联合申报国家级、省部级科研项目，协同发力应对传染病防控。 对公司当年业绩的影响：本协议属于意向性合作范畴，对公司 2025 年度 及未来业绩不构成直接影响，对公司业绩的具体影响需视下一步具体项目推进 和实施情况来确定。 履约的重大风险及不确定性： 本协议的签订对双方长期合作具有指导性意义，确立了战略合作伙伴关系， 为后续推进具体项目合作奠定重要基础，本次签订的战略合作协议属于意向性 合作协议，具体合作内容以双方签订的项目合作合同为准。协议履行过程中， 若受行业政策调整、市场环境变化等不可预见因素或不可抗力影响，可能导致 协 ...

Core Insights - Chengda Biologics (688739.SH) has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases [1] - The collaboration aims to jointly apply for national and provincial-level research projects, enhancing efforts in infectious disease prevention and control [1] - This strategic partnership integrates top resources in pathogen research from the Institute of Microbiology with the existing vaccine development platform of the company, accelerating the development of vaccines and biopharmaceuticals for emerging infectious diseases [1]

Core Viewpoint - Chengda Bio (688739) has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases and vector-borne disease prevention [1] Group 1 - The cooperation aims to jointly apply for national and provincial-level research projects to enhance efforts in infectious disease prevention and control [1] - The agreement is categorized as an intention-based collaboration and does not have a direct impact on the company's performance for 2025 and beyond [1]

Core Insights - Chengda Biological (688739.SH) has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases [2] Group 1 - The collaboration will concentrate on the prevention of vector-borne infectious diseases [2] - Both parties will jointly apply for national and provincial-level research projects [2] - The partnership aims to enhance efforts in infectious disease prevention and control [2]

格隆汇10月21日丨成大生物(688739.SH)公布，公司与中国科学院微生物研究所(简称"微生物所")于近日 签署《战略合作协议》(简称"本协议")，双方聚焦新发突发传染病领域，重点围绕虫媒传染病预防，联 合申报国家级、省部级科研项目，协同发力应对传染病防控。 本次战略合作整合了微生物所病原学研究顶尖资源，与公司现有疫苗研发平台形成协同效应，将加速新 发突发传染病疫苗及生物药研发进程，进一步丰富公司创新管线布局。 ...

Core Viewpoint - The company has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases, particularly vector-borne disease prevention [1] Group 1 - The agreement aims to jointly apply for national and provincial-level research projects to enhance efforts in infectious disease prevention and control [1] - This cooperation is categorized as an intention-based collaboration and does not have a direct impact on the company's performance for the year 2025 and beyond [1] - The specific impact on the company's performance will depend on the progress and implementation of subsequent projects [1]

Core Viewpoint - Chengda Biotech is focusing on the development, production, and sales of human vaccines, with a strong market presence in rabies and encephalitis vaccines, while also expanding its international business and exploring innovative technologies [1][2][3] Group 1: Company Overview - Chengda Biotech specializes in human vaccine research and production, with significant products including rabies and inactivated encephalitis vaccines [1] - The company has established production bases in Shenyang and Benxi, and has a dedicated R&D team of over 200 personnel [1] - Chengda Biotech's rabies vaccine has maintained a leading position in the domestic market since 2008, and it is the only provider of inactivated encephalitis vaccine in China [1] Group 2: Financial Performance - In the first half of 2025, the company reported revenue of 707 million yuan, a year-on-year decrease of 19.75% [1] - Total profit for the same period was 146 million yuan, down 46.37%, while net profit attributable to shareholders was 122 million yuan, a decline of 44.47% [1] Group 3: Governance and Strategic Initiatives - In February 2025, the company underwent a significant governance restructuring, changing its controlling shareholder to Shaoguan Gaoteng, which has no actual controller [2] - This governance change aims to enhance decision-making efficiency and market operations, while also exploring mergers and acquisitions for growth [2] Group 4: International Expansion - Chengda Biotech's international business has shown strong performance, with rabies vaccine sales increasing and market access expanded to over 30 countries, including new entry into Indonesia [2] - The company is actively pursuing market opportunities in countries along the Belt and Road Initiative, such as Brazil [2] Group 5: R&D and Innovation - The company has made significant progress in R&D, with several products at critical stages, including the human diploid rabies vaccine and various flu vaccines [3] - Chengda Biotech has established an "AI + Vaccine R&D Joint Laboratory" in collaboration with Zhongke Zhidong Taichu to explore deep applications of AI technology [3] - The marketing strategy for the inactivated encephalitis vaccine has shown effectiveness, with increased coverage and penetration in vaccination endpoints [3]

证券日报网讯 10月9日晚间，成大生物发布公告称，2025年9月份，公司通过上海证券交易所交易系统 以集中竞价交易方式回购公司股份208，478股，占公司总股本的比例约为0.05%。 ...

格隆汇10月9日丨成大生物(688739.SH)公布，截至2025年9月30日，公司通过上海证券交易所交易系统 以集中竞价交易方式已累计回购公司股份384,899股，占公司总股本的比例约为0.092%，回购成交的最 高价为29.61元/股，最低价为27.20元/股，已支付的资金总额为人民币10,789,216.56元（不含交易费用和 佣金）。 ...

Group 1 - The company Chengda Bio announced a share buyback of approximately 380,000 shares, accounting for about 0.092% of its total share capital, with a total expenditure of approximately 10.79 million RMB [1] - The highest and lowest prices for the repurchased shares were 29.61 RMB and 27.2 RMB per share, respectively [1] - As of the report, Chengda Bio's market capitalization stands at 11.3 billion RMB [1] Group 2 - For the year 2024, the company's revenue composition is entirely from biopharmaceuticals, with a 100% share [1]